Other management approaches might be feasible to accelerate the resume of the patient’s cycle depending on the type of myelosuppression of concerns, e.g. in the case of neutropenia, co-medication such as the administration of G-CSF to increase neutrophil count; for anemia, iron supplement/red-blood-cell transfusion/recombinant human erythropoietin erythropoiesis-stimulating agents (ESAs) to stimulate the production of red blood cells, and for thrombocytopenia, platelet transfusion as a treatment and thrombopoietin agents as prevention for thrombocytopenia. Here, EPO is linked to Thrombocytopenia.